Increased attention has been devoted to the management of neutropenia during the last 2 to 4 years. In this review we will discuss the introduction of effective novel therapies: hematopoietic growth factors (HGFs) for many forms of persistent neutropenia and intravenous (IV) immune globulin for autoimmune neutropenia (AIN).
Neutropenia is defined as a subnormal absolute number of neutrophils circulating in the blood. Determination of the absolute neutrophil count (ANC) requires the combination of a white blood cell (WBC) count and a differential WBC count. For example, if the WBC count is 8.0×109/L and the differential WBC count indicates 0.20 neutrophils, the ANC=8.0×0.20, or 1.6. Since the differential WBC count defines neutropenia, it is important that a hematologist review the blood smear and that an automated count not be exclusively relied on. The exact definition of the boundary between a normal ANC and neutropenia has ranged between 1.5 and